Wide Ranks

ANIX

Anixa Biosciences, Inc.

3.31

Top Statistics
Market Cap 106 M Forward PE -7.20 Revenue Growth 0.00 %
Current Ratio 11.31 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months Infinity
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 20 M Total Cash Per Share 0.6450 Total Debt 237000
Total Debt To Equity 1.15 Current Ratio 11.31 Book Value Per Share 0.6770
All Measures
Short Ratio 358.00 % Message Board Id finmb_263802 Shares Short Prior Month 593721
Return On Equity -0.5524 City San Jose Uuid d1a6c561-efcb-3db9-b4a0-d18906465c04
Previous Close 3.32 First Trade Date Epoch Utc 434 M Book Value 0.6770
Beta 0.8500 Total Debt 237000 Volume 66100
Price To Book 4.89 Last Split Date 1 B Fifty Two Week Low 2.15
Total Cash Per Share 0.6450 Shares Short Previous Month Date 1 B Target Median Price 8.50
Max Age 86400 Recommendation Mean 1.50 Sand P52 Week Change 0.3133
Target Mean Price 8.50 Net Income To Common -12361000 Short Percent Of Float 0.0213
Implied Shares Outstanding 32 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 125950 Average Volume10days 125950 Total Cash 20 M
Next Fiscal Year End 1 B Held Percent Insiders 0.0505 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 3.32
Target Low Price 7.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 3.25
Open 3.36 Free Cashflow -4303375 State CA
Dividend Yield 0.00 % Return On Assets -0.3465 Time Zone Short Name EST
Trailing Eps -0.3900 Day Low 3.30 Address1 3150 Almaden Expressway
Shares Outstanding 32 M Price Hint 4 Target High Price 10.00
Website https://www.anixa.com 52 Week Change -0.0090 Average Volume 86135
Forward Eps -0.3600 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 1055.60 % Last Split Factor 1:25 Regular Market Day High 3.44
Is_sp_500 False Profit Margins 0.00 % Debt To Equity 1.15
Fifty Two Week High 5.13 Day High 3.44 Shares Short 411556
Regular Market Open 3.36 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.0128 Operating Cashflow -8377000
Currency USD Time Zone Full Name America/New_York Market Cap 106 M
Is_nasdaq_100 False Zip 95118 Quote Type EQUITY
Industry Biotechnology Long Name Anixa Biosciences, Inc. Regular Market Day Low 3.30
Held Percent Institutions 0.1746 Current Price 3.31 Address2 Suite 250
Financial Currency USD Current Ratio 11.31 Industry Disp Biotechnology
Number Of Analyst Opinions 2 Country United States Float Shares 30 M
Two Hundred Day Average 3.10 Enterprise Value 84 M Price To Sales Trailing12 Months Infinity
Forward PE -7.20 Regular Market Volume 66100 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Anixa Biosciences, Inc., a clinical-stage biotechnology company, focuses on the treatment and prevention of cancer.

Its therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T) technology.

The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – primarily triple negative breast cancer (TNBC), the lethal form of the disease, as well as a vaccine to prevent ovarian cancer.

Its vaccine technologies focus on immunizing against retired proteins that found to be expressed in certain forms of cancer.

The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018.

Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.